{
    "clinical_study": {
        "@rank": "26745", 
        "arm_group": {
            "arm_group_label": "Single Oral MDV3100 dose", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A study to investigate the excretion routes of radio-labelled MDV3100."
        }, 
        "brief_title": "A Study to Explore the Routes of Elimination of MDV3100", 
        "completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of MDV3100"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index within 18.5 to 30.0kg/m2\n\n          -  Regular defecation pattern (minimum once per 2 days).\n\n          -  Subject must be non-fertile, i.e., surgically sterilized or must practice an adequate\n             contraceptive method to prevent pregnancies as defined in the protocol.\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to MDV3100, or any components of the formulation\n             used.\n\n          -  Any of the liver function tests above the upper limit of normal. A retest to confirm\n             the result may be performed once.\n\n          -  Any clinically significant history of asthma, eczema, any other allergic condition or\n             previous severe hypersensitivity to any drug (excluding non-active hay fever).\n\n          -  Abnormal pulse and/or blood pressure measurements at the pre-study visit as follows:\n             Pulse <40 or >90 bpm; mean systolic blood pressure >140 mmHg ; mean diastolic blood\n             pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has\n             been resting in supine position for 5 min; pulse will be measured automatically).\n\n          -  A QTc interval of > 430 ms after repeated measurements (consistently after duplicate\n             measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmias or torsades de pointes, structural heart disease, or a family history of\n             Long QT Syndrome (LQTS).\n\n          -  Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural\n             and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the\n             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day).\n\n          -  Regular use of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3\n             months prior to admission to the Clinical Unit.\n\n          -  Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.\n\n          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays\n             of thorax and bony skeleton (excluding spinal column)), during work or during\n             participation in a clinical study in the previous year."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911715", 
            "org_study_id": "9785-CL-0001", 
            "secondary_id": "2011-000089-37"
        }, 
        "intervention": {
            "arm_group_label": "Single Oral MDV3100 dose", 
            "description": "Oral", 
            "intervention_name": "MDV3100", 
            "intervention_type": "Drug", 
            "other_name": [
                "Xtandi", 
                "enzalutamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Mass Balance", 
            "MDV3100", 
            "Xtandi", 
            "Enzalutamide", 
            "Metabolism", 
            "Excretion"
        ], 
        "lastchanged_date": "July 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471GP"
                }, 
                "name": "PRA International"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 \u00b5Ci) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Operation Senior Research Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "description": "Time to attain Cmax (tmax)", 
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Time to attain Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Time to reach quantifiable concentrations (tlag)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by AUC from the time of dosing to the last measurable concentration (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by AUC extrapolated to infinity (AUC0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Terminal Disposition Rate Constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent terminal elimination half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent total body clearance after extra vascular dosing (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by blood-to-plasma ratio (Ratio Cb/p)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "measure": "Assessment of 14C recovery in urine", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (17 times)"
            }, 
            {
                "measure": "Assessment of 14C recovery in feces", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (16 times)"
            }, 
            {
                "measure": "Assessment of total 14C recovery (urine and feces combined) within 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (17 times for urine and 16 times for feces)"
            }, 
            {
                "measure": "Assessment of total 14C recovery (urine and feces combined) after Time of last quantifiable concentration (tlast)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (17 times for urine and 16 times for feces)"
            }, 
            {
                "description": "PK of MDV3100, MDPC0001, and MDPC0002 in plasma based on validated LC-MS/MS methods:\nIn plasma: Cmax, tmax, tlag, AUC0-t, AUC0-inf, \u03bbz, t1/2, CL/F (parent only), and Vz/F (parent only)\nThe ratios of AUCMDV3100/AUC14C , AUCMDPC0001/AUCMDV3100 and AUCMDPC0001/AUC14C (and the same for MDPC0002) will be calculated", 
                "measure": "Assessment of Pharmacokinetic profile of MDV3100 and metabolites in plasma", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (21 times)"
            }, 
            {
                "description": "PK of MDV3100, MDPC0001, and MDPC0002 in urine based on validated LC-MS/MS methods:\nIn urine: Cumulative amount excreted in urine from time zero to the last measurable concentration after dosing (Ae0-t), Renal clearance (CLR), Percent of dose excreted in urine from time zero to the last measurable concentration after dosing (Ae0-t%), Cumulative amount excreted in urine from time zero extrapolated to infinity (Ae0-inf), Percent of dose excreted in urine from time zero extrapolated to infinity (Ae0-inf%)\nThe ratios of AUCMDV3100/AUC14C , AUCMDPC0001/AUCMDV3100 and AUCMDPC0001/AUC14C (and the same for MDPC0002) will be calculated", 
                "measure": "Assessment of Pharmacokinetic profile of MDV3100 and metabolites in urine", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (17 times)"
            }, 
            {
                "description": "Identification and possible quantification of metabolites in plasma, and if applicable, in urine and feces", 
                "measure": "Metabolic Profile: Profiling of possible metabolites of MDV3100 in plasma, urine, and feces", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 78 (14 times)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety as assessed by recording adverse events, laboratory assessments, vital signs and electrocardiograms (ECGs)", 
            "safety_issue": "No", 
            "time_frame": "Day 1 through Day 78"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}